Maravai Lifesciences Holdings, Inc. cash flow statement
In fiscal 2025, Maravai Lifesciences Holdings, Inc.'s operations generated −$57.6m of cash; it spent $13.1m on capital projects, leaving free cash flow of −$70.7m.
Cash flow statement
| Fiscal year | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 24 | 152 | 369 | 536 | 126 | 7 | −58 | −25 |
| Depreciation and amortisation | 4 | 6 | 6 | 8 | 13 | 21 | 24 | 22 |
| Stock-based pay | 2 | 25 | 10 | 19 | 35 | 49 | 30 | 30 |
| Capital spending | 17 | 25 | 15 | 17 | 66 | 30 | 13 | 11 |
| Free cash flow | 7 | 127 | 354 | 519 | 61 | −22 | −71 | −36 |
| Free cash flow after stock pay | 5 | 102 | 343 | 500 | 26 | −72 | −101 | −66 |
| Share buybacks | 0 | 34 | 0 | 0 | — | — | — | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 13 | −15 | −9 | −10 | −15 | −23 | 9 | 4 |
| Depreciation and amortisation | 5 | 5 | 6 | 6 | 6 | 6 | 5 | 5 |
| Stock-based pay | 13 | 11 | 10 | 7 | 9 | 4 | 7 | 10 |
| Capital spending | 9 | 6 | 5 | 3 | 4 | 2 | 4 | 0 |
| Free cash flow | 5 | −20 | −14 | −13 | −19 | −25 | 4 | 4 |
| Free cash flow after stock pay | −9 | −31 | −24 | −20 | −28 | −29 | −3 | −7 |
Compare with peers
- Cytek Biosciences, Inc. cash flow
- Cryoport, Inc. cash flow
- Mesa Laboratories Inc cash flow
- Schrodinger, Inc. cash flow
- Grail, Inc. cash flow
Head to head: CTKB vs MRVICYRX vs MRVIMLAB vs MRVIMRVI vs SDGR
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies